Benzinga Novo Nordisk Loses Momentum As Eli Lilly Pulls Ahead In Weight-Loss Wars
Novo Nordisk's stock has dropped 41% YTD as it lowered sales growth and trimmed 2025 guidance due to competition and patent expiration. read more
Novo Nordisk's stock has dropped 41% YTD as it lowered sales growth and trimmed 2025 guidance due to competition and patent expiration. read more